These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 12213870

  • 1. Short-term suppression of GH and IGF-I levels improves gonadal function and sperm parameters in men with acromegaly.
    Colao A, De Rosa M, Pivonello R, Balestrieri A, Cappabianca P, Di Sarno A, Rochira V, Carani C, Lombardi G.
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4193-7. PubMed ID: 12213870
    [Abstract] [Full Text] [Related]

  • 2. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A, Pivonello R, Cappabianca P, Briganti F, Tortora F, Auriemma RS, De Martino MC, Marzullo P, Lombardi G.
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [Abstract] [Full Text] [Related]

  • 3. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.
    Waśko R, Ruchała M, Sawicka J, Kotwicka M, Liebert W, Sowiński J.
    J Endocrinol Invest; 2000 Jan; 23(1):12-8. PubMed ID: 10698045
    [Abstract] [Full Text] [Related]

  • 4. GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide.
    Attanasio R, Barausse M, Cozzi R.
    J Endocrinol Invest; 2001 Apr; 24(4):209-16. PubMed ID: 11383906
    [Abstract] [Full Text] [Related]

  • 5. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA.
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [Abstract] [Full Text] [Related]

  • 6. [Outcome of somatostatin analogue treatment in acromegaly].
    Mondok A, Tóth M, Patócs A, Szücs N, Igaz P, Pusztai P, Czirják S, Beko G, Gláz E, Rácz K, Tulassay Z.
    Orv Hetil; 2009 Aug 02; 150(31):1457-62. PubMed ID: 19617182
    [Abstract] [Full Text] [Related]

  • 7. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).
    Baldelli R, Colao A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E, Ferretti E, Ferone D, Gaia D, Camanni F, Lombardi G, Tamburrano G.
    J Clin Endocrinol Metab; 2000 Nov 02; 85(11):4099-103. PubMed ID: 11095439
    [Abstract] [Full Text] [Related]

  • 8. Effects of growth hormone replacement therapy on IGF-related parameters and on the pituitary-gonadal axis in GH-deficient males. A double-blind, placebo-controlled crossover study.
    Juul A, Andersson AM, Pedersen SA, Jørgensen JO, Christiansen JS, Groome NP, Skakkebaek NE.
    Horm Res; 1998 Nov 02; 49(6):269-78. PubMed ID: 9623518
    [Abstract] [Full Text] [Related]

  • 9. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide.
    Suliman M, Jenkins R, Ross R, Powell T, Battersby R, Cullen DR.
    J Endocrinol Invest; 1999 Jun 02; 22(6):409-18. PubMed ID: 10435849
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Protonotariou A, Lytras A.
    Neuroendocrinology; 2006 Jun 02; 83(3-4):249-57. PubMed ID: 17047390
    [Abstract] [Full Text] [Related]

  • 12. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly.
    Attanasio R, Baldelli R, Pivonello R, Grottoli S, Bocca L, Gasco V, Giusti M, Tamburrano G, Colao A, Cozzi R.
    J Clin Endocrinol Metab; 2003 Nov 02; 88(11):5258-65. PubMed ID: 14602759
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly.
    Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M.
    Clin Endocrinol (Oxf); 2008 Mar 02; 68(3):473-80. PubMed ID: 17941902
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
    Caron P, Morange-Ramos I, Cogne M, Jaquet P.
    J Clin Endocrinol Metab; 1997 Jan 02; 82(1):18-22. PubMed ID: 8989225
    [Abstract] [Full Text] [Related]

  • 17. Results of a two-year treatment with slow release lanreotide in acromegaly.
    Cannavò S, Squadrito S, Curtò L, Almoto B, Vieni A, Trimarchi F.
    Horm Metab Res; 2000 Jun 02; 32(6):224-9. PubMed ID: 10898551
    [Abstract] [Full Text] [Related]

  • 18. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients.
    Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G.
    J Clin Endocrinol Metab; 2006 Jun 02; 91(6):2112-8. PubMed ID: 16537687
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients.
    Marzullo P, Ferone D, Di Somma C, Pivonello R, Filippella M, Lombardi G, Colao A.
    Pituitary; 1999 Jun 02; 1(2):115-20. PubMed ID: 11081189
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.
    Colao A, Marzullo P, Ferone D, Marinò V, Pivonello R, Di Somma C, Di Sarno A, Giaccio A, Lombardi G.
    J Endocrinol Invest; 1999 Jan 02; 22(1):40-7. PubMed ID: 10090136
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.